RESUMO
Objective: To explore the protective effect of formula of Gougancai decoction (FGD) on acute liver injury induced by carbon tetrachloride (CCl4) in rats, in order to provide basis for the development of pharmaceutical preparations or healthcare products. Method: Sixty rats were randomly divided into normal group, Silymarin group (120 mg·kg-1) and FGD groups (475, 950, 1 900 mg·kg-1). The normal group and the model group were given equal volume of saline by gavage, while the other groups were administered with the corresponding dose of drugs according to the body weight. After 10 days, the acute liver injury model was established with 12% carbon tetrachloride peanut oil solution (5 mL·kg-1), except the normal group. All of the rats were put to death to collect serum and liver tissues. The contents of aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP), total bilirubin (TBIL), malondialdehyde (MDA), superoxide dismutase (SOD) and glutathione peroxidase (GSH-Px) were detected by biochemical methods, the levels of tumor necrosis factor-alpha (TNF-α), interleukin-1β (IL-1β) and interleukin-6 (IL-6) in liver tissues were determined by enzyme-linked immunosorbnent assay(ELISA). Nuclear factor-κB (NF-κB) and peroxisome proliferator-activated receptor-γ (PPAR-γ) protein expression in liver tissues were detected by Western blot, and htoxylin eosin (HE) staining was used to observe the variation of liver histopathological. Result: Compared with the normal group, the serum activities of AST, ALT, ALP and the content of TBIL, MDA in the model group were significantly increased (Pα, IL-1β, IL-6 in liver tissue were remarkably increased (PPκB was enhanced in liver tissue (Pγ was down-regulated (PPPα, IL-1β, IL-6 (PPκB (PPγ (PPConclusion: FGD has a protective effect on CCl4-induced acute liver injury in rats, and its mechanism may be related to the activation of PPAR-γ and the inhibition of NF-κB signaling pathway, with anti-inflammatory and anti-oxidative effects.
RESUMO
The efficacy and safety of enoxaparin (ENOX) in percutaneous coronary intervention (PCI) for ST-elevation myocardial infarction (STEMI) remains unaddressed. The primary endpoint evaluated was myocardial infarction (MI) or death. The secondary endpoint was defined as major bleeding complications. Studies comparing the differences in the efficacy and safety of ENOX versus unfractionated heparin (UFH) in PCI for the treatment of STEMI were evaluated. We presented the odds ratios for individual studies and performed heterogeneity, quality assessment, and publication bias analysis. This meta-analysis examined four randomized controlled trials (RCTs), and 5585 patients were included (2334 ENOX patients and 3251 UFH patients). The follow-up period of the endpoints was 30 or 90 days. Compared with UFH, ENOX significantly reduced the incidence of MI (OR, 0.74; P<0.01) and death (OR, 0.74; P<0.03), while there was no significant difference between the two treatments on major bleeding (OR,0.81; P=0.33). The findings from this meta-analysis suggested that the efficacy and safety of ENOX in the treatment of STEMI patients undergoing PCI were significantly better than patients treated with UFH. According to this meta-analysis, ENOX is the preferred anticoagulant for STEMI patients receiving PCI compared to UFH.
RESUMO
The effect of heart-type fatty acid binding protein (H-FABP) remains unclear on the quality of the prognoses of patients with acute coronary syndrome (ACS). The authors searched the EMBASE, PubMed, Cochrane Library, and Medline electronic databases from their respective inceptions throughout June 2017. Odds ratios were pooled from individual studies, and conducted heterogeneity analysis, quality assessment, and publication bias analysis. A total of four studies with 1,994 patients were included (554 positive patients; 1,440 negative patients). Pooled analysis of these studies showed that patients positive for H-FABP had higher incidence for mortality (OR, 6.39; p<0.01) and cardiac events (OR, 3.94; P<0.01) than negative patients, but myocardial infarction (MI) (OR, 1.43; P=0.32) showed no significant differences. ACS patients positive for H-FABP had higher rates in cardiac events and mortality. The incidence of MI showed no significant difference, possibly because this study was based on limited data from randomized studies. Additional substantial randomized controlled trials certainly needed to verify these discovery.
